This breakthrough is expected to give rise to novel therapies against aggressive forms of cancer, such as Burkitt’s lymphoma (BL). More prevalent in Africa than in the United States and Western ...
26don MSN
Genmab A/S (Nasdaq: GMAB) said on Monday that Johnson & Johnson (J&J) has decided not to exercise its option to obtain a ...
While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab’s rigorous portfolio ...
Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of HexaBody-CD38. “While we are disappointed that J&J has decided not to advance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback